Cancer Treatment Today

There is little literature supporting the use of Zolnza for gliolastoma. A recent study for recurrent disease by Galanis et al concluded that vorinostat monotherapy is well tolerated in patients with recurrent GBM and has modest single-agent activity. Histone acetylation analysis and RNA expression profiling indicate that vorinostat in this dose and schedule affects target pathways in GBM. Additional testing of vorinostat in combination regimens is warranted. A study has been completed but not yet published:Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme, NCT00238303.  Zolinza is beginning studies in combiantion and early results are beginning to appears, but not all have been encouraging. For example, Friday et al concluded: “further evaluation of the vorinostat-bortezomib combination in GBM patients in this dose and schedule is not recommended. ”

J.C.Easaw et al,  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme Curr Oncol. 2011 June; 18(3): e126–e136.

J. Polvka et a, New Molecularly Targeted Therapies for Glioblastoma Multiforme
Anticancer Res Jul 1, 2012:2935-2946

E.Galanis et al, Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study JCO April 20, 2009 vol. 27 no. 12 2052-2058

Bret B. Friday et al, Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study  Neuro Oncol (2012) 14 (2): 215-. Zolinza is beginning studies in combination and early results are beginning to appears, but not all have been encouraging. For example, Friday et al concluded: “further evaluation of the vorinostat-bortezomib combination in GBM patients in this dose and schedule is not recommended. ”

J.C.Easaw et al,  Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme Curr Oncol. 2011 June; 18(3): e126–e136.

J. Polvka et a, New Molecularly Targeted Therapies for Glioblastoma Multiforme
Anticancer Res Jul 1, 2012:2935-2946

E.Galanis et al, Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study JCO April 20, 2009 vol. 27 no. 12 2052-2058

Bret B. Friday et al, Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study  Neuro Oncol (2012) 14 (2): 215-

For Layl version see here